Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02387996 · FLOW

Participant flow

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer · Source last updated 2022-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W
    id
    FG000
    title
    Nivolumab 3 mg/kg
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        167
      type
      Disease Progression
    2. reasons
      1. group Id
        FG000
        num Subjects
        31
      type
      Study Drug Toxicity
    3. reasons
      1. group Id
        FG000
        num Subjects
        39
      type
      Adverse Event Unrelated to Study Drug
    4. reasons
      1. group Id
        FG000
        num Subjects
        20
      type
      Participant Request to Discontinue Treatment
    5. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Subject Withdrew Consent
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Lost to Follow-up
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Poor/Non-Compliance
    8. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Other Reasons
    9. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        270
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      comment
      Completed=continuing in the study treatment
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        270
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W
    id
    FG000
    title
    Nivolumab 3 mg/kg
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        167
      type
      Disease Progression
    2. reasons
      1. group Id
        FG000
        num Subjects
        31
      type
      Study Drug Toxicity
    3. reasons
      1. group Id
        FG000
        num Subjects
        39
      type
      Adverse Event Unrelated to Study Drug
    4. reasons
      1. group Id
        FG000
        num Subjects
        20
      type
      Participant Request to Discontinue Treatment
    5. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Subject Withdrew Consent
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Lost to Follow-up
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Poor/Non-Compliance
    8. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Other Reasons
    9. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        270
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      comment
      Completed=continuing in the study treatment
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        270
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice